Articles tagged with Flu Vaccines
The COVID-19 pandemic has led to reduced influenza reporting, but vaccination and strengthened surveillance are critical for a possible resurgence. Research highlights the importance of flu vaccination and early testing for non-influenza respiratory viruses.
A cell-based quadrivalent influenza vaccine has effectively provided protection against the flu in children and adolescents. The study found that the vaccine produced a sufficient immune response in children aged two to 18 years, with an overall vaccine efficacy of 54.6 per cent.
New research from an international team of scientists found that poor timing of influenza vaccination campaigns in Brazil led to increased premature births, lower birth-weight babies, and the need for more cesarean sections. The study suggests that earlier flu vaccination campaigns could better protect pregnant women and their babies.
Researchers developed an Internet information system, virusMED, to provide a comprehensive picture of viruses' most important regions. The database contains over 800 strains from 75 different families, including SARS-CoV-2, influenza, Ebola, and HIV-1, enabling scientists to respond quickly and effectively against the next pathogen.
A team of Black female clinicians and researchers propose an Afrocentric health-promotion approach to combat vaccine hesitancy among Black Canadians. The LEAPS framework encourages providers to respect patients' values, views, and concerns when offering vaccine recommendations.
Racial and ethnic disparities in vaccine uptake have persisted over the last decade, highlighting the urgent need to achieve equity in immunization rates. Concerted efforts are needed to address socio-economic disparities, particularly among adults 65 years or older.
The authors argue that intranasal COVID-19 vaccines could provide additional layers of protection by eliciting immunoglobulin A and resident memory cells in the nasal passages. An ideal vaccination strategy may consist of an intramuscular vaccine combined with an intranasal booster, offering a dual approach to combat respiratory viruses.
A patient with no previous history of facial nerve palsy developed two episodes of Bell's palsy after receiving Pfizer-BioNTech COVID-19 vaccine doses. The author suggests a potential link between the vaccine and Bell's palsy, emphasizing cautious use for those at risk.
The 1918 influenza pandemic and COVID-19 share similar patterns in mortality comparisons due to population adjustments for average life years lost. The study assesses the cumulative health impacts of interventions and provides a basis for decision-making.
A recent study published in the British Journal of Health Psychology found that providing information on the efficacy of COVID-19 vaccines can significantly increase willingness to be vaccinated. The research showed that adults who received information about vaccine effectiveness scored 20% higher on a measure of willingness to be vacc...
The flu vaccine has been found to protect against severe effects of COVID-19, including ICU admissions, sepsis, and strokes. Patients vaccinated against flu were less likely to visit emergency departments and be admitted to ICUs.
A single-dose, intranasal COVID-19 vaccine has been shown to fully protect mice against lethal infection and block animal-to-animal transmission of the virus. The vaccine targets mucosal cells in the nasal passages and airways, where SARS-CoV-2 infections occur.
Researchers found that vaccines produced in chicken eggs induce an antibody response against a glycan called N-acetyllactosamine (LacNAc), which is not typically targeted by the immune system. This unexpected finding may impact the effectiveness of flu vaccines grown in eggs.
A third dose of COVID-19 vaccine significantly increased antibody levels in organ transplant recipients who had a suboptimal response to standard vaccination. The study found that booster doses may be necessary for these patients, similar to hepatitis B and influenza vaccinations.
Researchers identified conserved parts of the 2009 H1N1 pandemic flu virus that triggered strong and effective immune responses. These responses can be harnessed for a universal flu vaccine targeting stable, conserved areas of the HA protein.
A new universal vaccine may improve cross protection against different flu virus strains in adults and seniors with pre-existing immunity. The grant aims to test this theory in aged populations, addressing a significant public health concern.
Researchers found broadly neutralizing antibodies that target two conserved regions of the H1N1 influenza virus, which also neutralize various other strains. These findings suggest that vaccines targeting these regions could protect against a broader array of flu strains.
The NIH has launched a clinical trial for a novel influenza vaccine that offers long-lasting protection against multiple flu virus strains. The vaccine, known as FluMos-v1, is designed to stimulate antibodies against the HA protein using nanoparticle scaffolds.
A new study shows that the pandemic has boosted older Canadians' willingness to receive the flu shot, with 20% of 50-64 year olds and 8% of those 65+ now more likely to get vaccinated. However, some respondents cited concerns about safety due to COVID-19 co-circulation or fear of exposure.
The vaccine has the potential to improve seasonal flu vaccine effectiveness, produce vaccines faster and use smaller doses. It achieved a strong immune response in mice, providing protection against two different strains of influenza.
A University of Queensland study has found that reduced levels of metabolic hormone leptin are associated with poor vaccine antibody responses in both young and older individuals. The research could lead to the development of new strategies for improving vaccine protection in vulnerable populations.
Researchers identified specific influenza targets to protect Aboriginal and Torres Strait Islander people from severe disease through a universal T cell-based vaccine. The study aims to harness immune responses to protect high-risk populations, including those with high HLA-A*24:02 protein prevalence.
A new study finds that only half of adults with cardiovascular disease report getting a flu shot annually, highlighting the need for better vaccination efforts. Patients with certain conditions and those who attend college are more likely to receive a flu vaccine.
Researchers developed an intranasal influenza vaccine using recombinant hemagglutinin and found it enhanced immune responses in mice. The vaccine showed superior immunoenhancing properties and conferred protection against both same and different virus strains.
A nationwide survey of US patients on dialysis found that 20% were hesitant to receive a COVID-19 vaccine, with rates higher among certain groups. The study highlights the need for targeted outreach efforts to address concerns about vaccine safety and side effects.
A new UC San Diego study found that Republicans' willingness to get vaccinated increased over time, while Democrats' views remained stable. The study also showed that Republicans were less trusting of media and viewed the COVID-19 virus as less threatening than Democrats.
Research at UCLA Health Sciences suggests that elderly patients of female physicians are more likely to be vaccinated against the flu and COVID-19. The trend holds across all racial and ethnic groups studied, with Black patients being about 14 percentage points less likely to be vaccinated than white patients.
Researchers have developed next-generation influenza vaccines that protect against a wide variety of seasonal and pandemic strains, including avian viruses H5N1 and H7N9. These nanoparticle-based vaccines spur strong immune responses in animal trials, potentially lowering the risk of bad flu seasons.
A recent study found that people who received a flu shot last flu season were significantly less likely to test positive for COVID-19 and had fewer complications if they did. Researchers reviewed medical charts for over 27,000 patients and discovered a strong association between flu vaccination and reduced COVID-19 infections.
MIT researchers develop a vaccination strategy that creates an army of T cells ready at the respiratory tract's mucosal surfaces, boosting immune responses. The approach uses albumin proteins to ferry vaccines across mucosal barriers, offering a quicker response to viral invaders and potential treatment for lung cancer.
A recent study from Washington State University found that doctor-patient communication plays a crucial role in building trust and increasing vaccination rates during a pandemic. By discussing the pros and cons of vaccines, doctors can help patients make informed decisions and ultimately receive vaccinations.
A nanoparticle-based vaccine has been shown to produce protective antibodies against multiple H1 and H3 influenza A viruses in nonhuman primates. The vaccine's broad immunity suggests it may provide long-term protection, offering a promising solution to the challenge of creating a universal flu vaccine.
Researchers have developed a vaccine that demonstrates promising signs of protection against more than a dozen swine flu strains and outperforms leading commercial vaccine. The Epigraph vaccine stimulates an immune response against multiple closely related viral strains, providing broader immunity and better cellular-level responses.
A novel algorithm, Epigraph, has been used to create a broadly reactive influenza vaccine for swine flu and may also be applicable to developing a pan-coronavirus vaccine. The immune responses to the vaccine showed promising breadth against diverse viral variants.
A new study published in The Lancet Healthy Longevity found significant racial and ethnic disparities in the uptake of seasonal flu vaccines among people aged 65 and over in the USA. Among those who received a vaccine, minorities were 26-32% less likely to receive the High Dose Vaccine, which is more effective in older adults.
A new study links the 2019-2020 flu season to a more transmissible strain of Type B influenza virus. Younger individuals were disproportionately affected due to limited exposure to other B viruses, highlighting the need for targeted vaccination and preparedness strategies.
Researchers at University of Missouri-Columbia found that flu vaccination significantly reduces COVID-19 symptoms and complications in children. The review of over 900 pediatric patients with COVID-19 showed that those who received the flu vaccine had lower odds of experiencing respiratory problems or severe disease.
A new intranasal influenza vaccine demonstrated a durable immune response in a Phase 1 study, producing higher antibody levels compared to oral vaccination. The vaccine induced mucosal immunity and neutralizing antibodies at 26 weeks after vaccination, with sustained protection lasting up to five years.
A nationwide survey conducted by UC Davis found that over a third of Americans are unlikely or hesitant to get the COVID-19 vaccine due to concerns about its safety and effectiveness. The study also identified demographic characteristics, media consumption habits, and political affiliations as factors influencing vaccination intentions.
A study by University of Georgia researchers found that state laws promoting flu vaccinations for hospital workers can substantially reduce the number of influenza-related deaths. States with vaccination mandates saw an average reduction in mortality of about two deaths per 100,000 persons, primarily among older adults.
A new study suggests that vaccinating people over 60 is the most effective way to mitigate mortality from COVID-19. The analysis shows that vaccinating older adults will most effectively reduce deaths, even if vaccination of younger adults is projected to avert the greatest incidence of disease.
A randomized clinical trial compared flu vaccine reactions in older adults, finding that injection-site pain was a common side effect. The study also revealed differences in reaction rates among various flu vaccine types.
A new study suggests that fact-checking labels from health institutions and research universities can positively impact attitudes toward vaccines. The study found that these labels generate more positive attitudes than misinformation alone, with perceived source expertise making a difference.
Research suggests that state laws requiring flu vaccination for hospital workers can reduce pneumonia and influenza mortality rates, particularly among the elderly. A quasi-experimental study found a 2.5% reduction in monthly pneumonia and influenza mortality rates after law implementation, averting approximately 1,822 deaths.
Researchers found that prosocial concerns drive higher vaccination rates in rural areas than urban ones. The study suggests emphasizing prosocial aspects of vaccination can reduce the rural-urban disparity in vaccination. Vaccination protects not only individuals but also communities, highlighting its social nature.
A survey conducted by the Lupus Research Alliance found that two-thirds of people with lupus would take a COVID-19 vaccine if it were free and deemed safe by scientists. However, 24% said they would not get vaccinated, citing concerns over side effects and safety, while 22% remained uncertain.
Research at the University of Chicago found that pre-existing flu immunity shapes antibody responses to influenza infections and vaccinations. The quality of these responses differs between individuals who are vaccinated or naturally infected, with vaccinated individuals generating more adaptable antibodies that target conserved regions.
A chimeric hemagglutinin (HA)-based vaccine targets the proximal part of the HA protein, neutralizing diverse influenza virus strains. The vaccine has produced strong and durable results in early-stage clinical trials, eliminating the need for revaccination.
A survey of 1,500 UK adults found that 64% would be likely to have a COVID-19 vaccination. The study identified factors associated with likelihood of acceptance, including previous flu vaccination and positive vaccination beliefs.
A recent study found that a high-dose flu vaccine is equally effective to a standard dose in reducing the risk of death or hospitalizations from heart or lung-related illnesses in people with heart disease. Researchers enrolled over 5,000 participants and found no significant difference between the two vaccine formulations.
A recent study reveals that only about 20% of young adults with a history of heart attack received an annual influenza vaccination, compared to 28% of those without heart attack. This finding highlights the importance of increasing flu vaccination rates among individuals with cardiovascular disease.
Researchers aim to boost protection against severe flu infection in babies under 6 months with a new vaccine approach.
A study published in Immunity explores polyreactive broadly neutralizing antibodies and their role against influenza viruses. The researchers found that these antibodies are commonly polyreactive and preferentially induced by novel and pandemic-level influenza viruses.
Researchers consider indirect protection strategies due to potential ineffectiveness in elderly and comorbid individuals. Indirect effects are harder to measure than direct effects, highlighting the need for evidence on vaccine impact before approval or soon after.
Current Covid-19 vaccine trials are not designed to detect a reduction in serious outcomes such as hospitalisations, intensive care use, or deaths. The trials evaluate mild disease and may not provide evidence of vaccine effectiveness in preventing severe illness or transmission.
A new study by Cornell researchers found that COVID-19 vaccine efficacy is a key factor in Americans' willingness to adopt the vaccine, with increased effectiveness leading to higher acceptance rates. The study also highlighted the impact of political endorsements and geopolitical factors on vaccine uptake.
A new study describes a vaccine that triggers an immune response against an influenza protein segment rarely mutated by the virus, raising the possibility of effective protection against seasonal and pandemic strains. The vaccine uses nanoparticles coated with flu proteins to train the immune system to create desired antibodies.
Influenza vaccination has shown promise in preventing cardiovascular complications from COVID-19, particularly in high-risk patients. Three ongoing trials are evaluating the cardioprotective effects of different influenza vaccine formulations and may inform future efforts to develop targeted interventions.
A UC Riverside study found that HPV vaccination mandates did not lead to increased vaccine uptake or equal access among diverse populations. Mandates aimed at standardizing age of uptake were ineffective in improving compliance rates, highlighting the need for more targeted strategies.
Researchers developed a T-cell-based vaccine strategy providing long-lasting, multi-pronged protection against multiple strains of influenza. The experimental vaccine administered through the nose delivered immune response by rallying T-cells in the lungs, offering potential for universal flu vaccine development.